COL10A1 Inhibitors
COL10A1 inhibitors constitute a comprehensive array of compounds that act either directly or indirectly to modulate COL10A1 expression by targeting specific signaling pathways crucial for its regulation. Sunitinib, a tyrosine kinase inhibitor, indirectly inhibits COL10A1 by suppressing VEGFR signaling, thereby impeding the angiogenic environment associated with COL10A1 expression. U0126, a MEK inhibitor, attenuates COL10A1 expression by specifically blocking the MAPK pathway, disrupting the downstream activation of ERK1/2, key components in the regulation of COL10A1. In a similar vein, SB203580, a p38 MAPK inhibitor, interferes with the p38 signaling pathway, disrupting the cascade leading to COL10A1 upregulation. LY294002 and Wortmannin, both PI3K inhibitors, impact the PI3K/AKT signaling pathway, suppressing COL10A1 expression by interrupting this pathway and inhibiting the downstream activation of AKT. A83-01, a TGF-β receptor inhibitor, interferes with TGF-β signaling, hindering COL10A1 indirectly by preventing the activation of TGF-β receptors.
Furthermore, Rapamycin, a mTOR inhibitor, inhibits COL10A1 indirectly by suppressing mTOR activation, disrupting the signaling cascade leading to COL10A1 upregulation. SP600125, a JNK inhibitor, suppresses COL10A1 by blocking the downstream activation of JNK, a key component in the regulation of COL10A1. Wortmannin and PD98059, both affecting the PI3K/AKT and MAPK pathways, respectively, present additional avenues for inhibiting COL10A1 expression. CAY10576, a STAT3 inhibitor, impacts the STAT3 signaling pathway, suppressing COL10A1 by blocking the downstream activation of STAT3. AS703026, an ERK1/2 inhibitor, attenuates COL10A1 expression by specifically inhibiting ERK1/2, key components in the regulation of COL10A1. Finally, SB431542, a TGF-β receptor inhibitor, interferes with TGF-β signaling, inhibiting COL10A1 indirectly by preventing the activation of TGF-β receptors.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $150.00 $920.00 | 5 | |
Tyrosine kinase inhibitor targeting multiple receptors, including those in angiogenesis pathways. Inhibits COL10A1 indirectly by suppressing vascular endothelial growth factor receptor (VEGFR) signaling, thereby limiting the angiogenic environment associated with COL10A1 expression. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
p38 MAPK inhibitor impacting the p38 signaling pathway. COL10A1 expression is modulated through p38 MAPK, and SB203580 hinders COL10A1 by preventing p38 activation, thus disrupting the signaling cascade leading to COL10A1 upregulation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
PI3K inhibitor affecting the PI3K/AKT signaling pathway. COL10A1 is influenced by PI3K/AKT signaling, and LY294002 suppresses COL10A1 expression by interrupting this pathway, inhibiting the downstream activation of AKT. | ||||||
A 83-01 | 909910-43-6 | sc-203791 sc-203791A | 10 mg 50 mg | $198.00 $650.00 | 16 | |
TGF-β receptor inhibitor that impedes TGF-β signaling. COL10A1 expression is influenced by TGF-β, and A83-01 inhibits COL10A1 indirectly by preventing the activation of TGF-β receptors, thus interfering with the signaling cascade leading to COL10A1 upregulation. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK inhibitor affecting the JNK signaling pathway. COL10A1 expression is modulated through JNK signaling, and SP600125 suppresses COL10A1 by blocking the downstream activation of JNK, thereby disrupting the signaling cascade leading to COL10A1 upregulation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
mTOR inhibitor impacting the mTOR signaling pathway. COL10A1 expression is regulated through mTOR signaling, and Rapamycin inhibits COL10A1 indirectly by suppressing mTOR activation, thus disrupting the signaling cascade leading to COL10A1 upregulation. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
PI3K inhibitor similar to LY294002, impacting the PI3K/AKT signaling pathway. COL10A1 is influenced by PI3K/AKT signaling, and Wortmannin suppresses COL10A1 expression by interrupting this pathway, inhibiting the downstream activation of AKT. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
MEK inhibitor influencing the MAPK pathway. COL10A1 is regulated by MAPK signaling, and PD98059 attenuates COL10A1 expression by blocking the downstream activation of ERK1/2, key components of this pathway. | ||||||
AS703026 | 1236699-92-5 | sc-364412 sc-364412A | 5 mg 10 mg | $80.00 $130.00 | ||
ERK1/2 inhibitor affecting the MAPK pathway. COL10A1 is regulated by MAPK signaling, and AS703026 attenuates COL10A1 expression by specifically inhibiting ERK1/2, key components of this pathway. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
TGF-β receptor inhibitor that impedes TGF-β signaling. COL10A1 expression is influenced by TGF-β, and SB431542 inhibits COL10A1 indirectly by preventing the activation of TGF-β receptors, thus interfering with the signaling cascade leading to COL10A1 upregulation. | ||||||